Engineered DNA-encoded PCSK9 inhibitors may provide an effective alternative for treating high cholesterol

Researchers have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream. Results of preclinical studies showed a significant cholesterol decrease, opening the door for further development of this approach as a simple, less frequent and cost-effective therapy.

from Top Health News -- ScienceDaily https://ift.tt/2FobM5q